Scroll for IMPORTANT SAFETY INFORMATION AND INDICATION
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site. Discontinue
EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
The most common adverse reaction occurring in ≥1% of subjects in clinical trials was application site pain, such as burning or stinging.
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in patients 2 years of age and older.
Reference: 1. EUCRISA® (crisaborole) Full Prescribing Information. December 2016.
Please see Full Prescribing Information.
PP-CRI-USA-0501-01 © 2017 Pfizer Inc.
All rights reserved. June 2017